Cell-Free DNA Hypermethylation in Patients with Acute Pancreatitis
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262110792 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Hassan Al-Mashat und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Aalborg University Hospital, 9000 Aalborg, Denmark. Hauptthemen laut MEDLINE: DNA Methylation, Pancreatitis, Cell-Free Nucleic Acids. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Resident Foundation at Aalborg University Hospital, Speciallæge Heinrick Koops Foundation, Aase, Ejnar Danielsens Foundation.
Abstract (Originalsprache)
Cell-free DNA (cfDNA) promoter hypermethylation shows promise as a blood-based biomarker for pancreatic cancer, and similar alterations may occur in acute pancreatitis (AP). This study investigated the cfDNA hypermethylation profile of AP patients over time, compared with healthy controls, and its association with AP severity markers. A prospective longitudinal study including hospitalized AP patients and healthy controls was conducted. Methylation-specific PCR of a 23-gene panel was performed on plasma collected at inclusion (T0), 6 weeks (T6W), 6 months (T6M), and 7–8 years (T8Y). Associations between gene hypermethylation and clinical markers of AP severity—CRP, leukocyte count, creatinine, hospital stay, and complications—were evaluated. AP patients had a significantly higher mean number of hypermethylated genes at T0 (7.4, 95% CI: 6.8–8.0) compared with the controls (3.3, 95% CI: 2.8–3.8; p < 0.01). The mean number decreased over time to 3.2 (95% CI: 2.4–4.1) at T8Y. Total hypermethylation was positively associated with CRP (ρ = 0.39; p = 0.0018), leukocytes (ρ = 0.35; p = 0.0052), and hospital stay (ρ = 0.27; p = 0.0375). AP patients exhibited significantly higher cfDNA hypermethylation at disease onset, which normalized over time. Total hypermethylation showed positive associations with several markers of AP severity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, Aalborg University Hospital, 9000 Aalborg, Denmark.
- Research Data and Biostatistics, Aalborg University Hospital, 9000 Aalborg, Denmark.
- Department of Molecular Diagnostics, Aalborg University Hospital, 9000 Aalborg, Denmark.
- Department of Clinical Medicine, Aalborg University, 9000 Aalborg, Denmark.
- Clinical Cancer Research Center, Aalborg University Hospital, 9000 Aalborg, Denmark.
ORCID-Profile: Daniel Roger Baddoo, Søren Lundbye-Christensen, Inge Søkilde Pedersen, Henrik B Krarup, Benjamin Emil Stubbe, Stine Dam Henriksen
Förderung
- Resident Foundation at Aalborg University Hospital
- Speciallæge Heinrick Koops Foundation, Aase
- Ejnar Danielsens Foundation
- Blegdalens Foundation
- Marie Pedersen and Jensine Heibergs Foundation
- Medical Advancement of Science Foundation
- Beckett Foundation
Zitieren
APA
Al-Mashat, H., Baddoo, D. R., Lundbye-Christensen, S., Madsen, P. H., Pedersen, I. S., Krarup, H. B., Stubbe, B. E., Thorlacius-Ussing, O., & Henriksen, S. D. (2025). Cell-Free DNA Hypermethylation in Patients with Acute Pancreatitis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262110792
Vancouver
Al-Mashat H, Baddoo DR, Lundbye-Christensen S, Madsen PH, Pedersen IS, Krarup HB, et al. Cell-Free DNA Hypermethylation in Patients with Acute Pancreatitis. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262110792
BibTeX
@article{AlMashat2025,
author = {Al-Mashat, Hassan and Baddoo, Daniel Roger and Lundbye-Christensen, Søren and Madsen, Poul Henning and Pedersen, Inge Søkilde and Krarup, Henrik B and Stubbe, Benjamin Emil and Thorlacius-Ussing, Ole and Henriksen, Stine Dam},
title = {Cell-Free DNA Hypermethylation in Patients with Acute Pancreatitis},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262110792}
}
EUVIMED